8-K: Werewolf Therapeutics Announces Board Changes: DiRocco to Resign, Singhal Appointed

Werewolf Therapeutics announces the resignation of director Derek DiRocco and the appointment of Anil Singhal to its Board of Directors.

Summary

• Derek DiRocco, M.D., has notified Werewolf Therapeutics of his intent to resign from the Board of Directors, effective upon the company's 2025 annual meeting of stockholders.
• Anil Singhal, Ph.D., has been appointed as a Class I director to serve until the 2025 annual meeting of stockholders.
• Dr. Singhal will also serve as a member of the Audit Committee.
• Dr. Singhal has over three decades of research and development experience in the biopharmaceutical industry and currently serves as the President and CEO of Trishula Therapeutics, Inc.
• He previously served as President and CEO of Adicet Bio, Inc. and as Vice President at AbbVie Inc.
• Dr. Singhal will receive $40,000 annual cash compensation for his service as a director and $7,500 for his service on the Audit Committee, prorated for the remaining portion of the Board service year.
• He was also granted an option to purchase 45,000 shares of the company's common stock at an exercise price of $1.40, vesting over three years.
• Dr. Singhal has entered into a standard indemnification agreement with the company.

Sentiment

Score: 7

Explanation: The announcement is neutral to slightly positive. The appointment of an experienced director is generally viewed favorably, while the resignation is framed as not due to any disagreement.

Positives

• The appointment of Anil Singhal, Ph.D., brings significant biopharmaceutical industry experience to Werewolf Therapeutics' Board of Directors.
• Dr. Singhal's experience includes leadership roles at multiple companies, including as CEO of Trishula Therapeutics and Adicet Bio, and as Vice President at AbbVie.
• His appointment to the Audit Committee could strengthen the company's financial oversight.

Industry Context

Changes in board composition are common in the biopharmaceutical industry as companies evolve and seek expertise relevant to their current stage of development. The appointment of Dr. Singhal, with his extensive experience in oncology and company leadership, suggests Werewolf Therapeutics is focused on advancing its oncology programs.

Comparison to Industry Standards

• Compensation for non-employee directors in the biopharmaceutical industry typically includes a mix of cash and equity.
• The annual cash compensation of $40,000 plus $7,500 for Audit Committee service is within the typical range for companies of Werewolf Therapeutics' size and stage.
• Granting stock options is a standard practice to align director interests with shareholder value.
• The vesting schedule of the stock options (one-third on the first anniversary, then equal monthly installments until fully vested on the third anniversary) is also typical.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced director positively.
• The changes do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Board of Directors, Anil Singhal, Derek DiRocco, Werewolf Therapeutics, Appointment, Resignation, Audit Committee, Biopharmaceutical